These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32574951)

  • 21. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
    Ineichen BV; Moridi T; Ewing E; Ouellette R; Manouchehrinia A; Stawiarz L; Ferreira D; Muehlboeck SJ; Kuhle J; Westman E; Leppert D; Hillert J; Olsson T; Kockum I; Piehl F; Granberg T
    J Intern Med; 2021 Aug; 290(2):473-476. PubMed ID: 33871105
    [No Abstract]   [Full Text] [Related]  

  • 22. Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Goldschmidt C; Fox RJ
    Neurology; 2021 Nov; 97(19):887-888. PubMed ID: 34504029
    [No Abstract]   [Full Text] [Related]  

  • 23. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level-NO.
    Arrambide G; Espejo C; Tintore M
    Mult Scler; 2015 Sep; 21(10):1240-2. PubMed ID: 26242692
    [No Abstract]   [Full Text] [Related]  

  • 24. Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Akgün K; Ziemssen T
    Mult Scler; 2020 May; 26(6):742-743. PubMed ID: 31144585
    [No Abstract]   [Full Text] [Related]  

  • 25. Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Soelberg Sorensen P; Sellebjerg F
    Mult Scler; 2016 Aug; 22(9):1112-3. PubMed ID: 27364323
    [No Abstract]   [Full Text] [Related]  

  • 26. Is CSF neurofilament light chain measurement relevant for MS?
    Matsui M
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32928895
    [No Abstract]   [Full Text] [Related]  

  • 27. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level - YES.
    Salzer J
    Mult Scler; 2015 Sep; 21(10):1239-40. PubMed ID: 25828757
    [No Abstract]   [Full Text] [Related]  

  • 28. Personalized medicine for multiple sclerosis: How to integrate neurofilament light chain levels in the decision?
    Villoslada P
    Mult Scler; 2021 Nov; 27(13):1967-1969. PubMed ID: 34612731
    [No Abstract]   [Full Text] [Related]  

  • 29. The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary.
    Hutchinson M
    Mult Scler; 2015 Sep; 21(10):1242-3. PubMed ID: 26242693
    [No Abstract]   [Full Text] [Related]  

  • 30. Serum neurofilament light as a prognostic marker for MS disability: Are we there yet?
    van Kempen ZLE; Kryscio RJ; Dalla Costa G
    Neurology; 2020 Jun; 94(23):1013-1014. PubMed ID: 32434864
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone.
    Krämer J; Wiendl H; Meuth SG; Albrecht P
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34348970
    [No Abstract]   [Full Text] [Related]  

  • 32. Tracking therapies in MS: More evidence in favor of neurofilament.
    Yeh EA; Sormani MP
    Neurology; 2020 Mar; 94(11):465-466. PubMed ID: 32047072
    [No Abstract]   [Full Text] [Related]  

  • 33. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
    Lycke JN; Karlsson JE; Andersen O; Rosengren LE
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
    Kuhle J; Disanto G; Lorscheider J; Stites T; Chen Y; Dahlke F; Francis G; Shrinivasan A; Radue EW; Giovannoni G; Kappos L
    Neurology; 2015 Apr; 84(16):1639-43. PubMed ID: 25809304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Loonstra FC; Verberk IMW; Wijburg MT; Wattjes MP; Teunissen CE; van Oosten BW; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    Ann Neurol; 2019 Aug; 86(2):322-324. PubMed ID: 31192473
    [No Abstract]   [Full Text] [Related]  

  • 36. Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Dalla Costa G; Martinelli V; Furlan R; Comi G
    Ann Neurol; 2019 Aug; 86(2):324. PubMed ID: 31187511
    [No Abstract]   [Full Text] [Related]  

  • 37. Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In Vivo Quantification Using Serum Neurofilament.
    Preziosa P; Schoonheim MM
    Neurology; 2021 Aug; 97(6):257-258. PubMed ID: 34088879
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.
    de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
    Acta Neurol Scand; 2019 May; 139(5):462-468. PubMed ID: 30740668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D supplementation and neurofilament light chain in multiple sclerosis.
    Holmøy T; Røsjø E; Zetterberg H; Blennow K; Lindstrøm JC; Steffensen LH; Kampman MT
    Acta Neurol Scand; 2019 Feb; 139(2):172-176. PubMed ID: 30317548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study.
    Bittner S; Steffen F; Uphaus T; Muthuraman M; Fleischer V; Salmen A; Luessi F; Berthele A; Klotz L; Meuth SG; Bayas A; Paul F; Hartung HP; Linker R; Heesen C; Stangel M; Wildemann B; Then Bergh F; Tackenberg B; Kuempfel T; Weber F; Zettl UK; Ziemann U; Tumani H; Groppa S; Mühlau M; Lukas C; Hemmer B; Wiendl H; Gold R; Zipp F;
    EBioMedicine; 2020 Jun; 56():102807. PubMed ID: 32460167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.